Liver transplantation for metastatic neuroendocrine tumors (Q38257944)

1 September 2017

1 reference

title

Liver transplantation for metastatic neuroendocrine tumors. (English)

1 reference

1 September 2017

Haniee Chung

1

1 reference

PubMed ID

25293619

1 September 2017

William C Chapman

series ordinal

2

1 reference

1 September 2017

1 January 2014

1 reference

1 September 2017

1 reference

1 September 2017

48

1 reference

1 September 2017

235-252

1 reference

Hepatic resection for metastatic neuroendocrine carcinomas

1 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Gastroenteropancreatic neuroendocrine tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Management of neuroendocrine liver metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Neuroendocrine hepatic metastases: does aggressive management improve survival?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Hepatic surgery for metastases from neuroendocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Glycemic control in patients with insulinoma treated with everolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. treatment of hepatic metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Interventional treatment of gastrointestinal neuroendocrine tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2014.05.003

10.1016/J.YASU.2014.05.003

7 January 2021

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25293619